June 7, 2017
The University of Pittsburgh reported that Pitt Innovators were issued 11 patents in May 2017.
US 9,655,980 “A Novel Theranostic Platform for Targeted Cancer Therapy and Drug Delivery Monitoring”
Former Pitt Assistant Professor of Radiology Mingfeng Bai, and presently an assistant professor at Vanderbilt University, together with research associate Pin Shao, has developed a compound that can monitor targeted drug delivery using molecular imaging. The patent covers the first functional quaterrylene dye and flourescent theranostic dendrimer platform. It will allow for long-term non-invasive therapeutic monitoring in a wide range of cancers. It will also be possible to conjugate various targeting molecules and drugs to the platform, providing the potential to transform the way cancer patients are treated and monitored and provide new capabilities in cancer research. The photostability study showed that the NIR theranostic dendrimer platform compounds have orders of magnitude higher photostability than FDA approved NIR fluorescent dye, ICG. In addition, cytotoxicity and cell imaging studies demonstrated that this photostable NIR theranostic dendrimer platform was highly biocompatible. For more information on this technology, including licensing, contact Maria Vanegas.
Below is a listing of all patents issued to Pitt Innovators in May 2017.
|9,636,007||Method and Apparatus for Aiding in the Diagnosis of Otitis Media by Classifying Tympanic Membrane Images||Alejandro Hoberman; Jelena Kovacevic, Nader Shaikh; Anupama Kuruvilla||Carolyn Weber||Available for Licensing|
|9,642,858||Use of Resazurin, or Analogs Thereof, for Antibacterial Therapy||Joseph Horzempa; Gerard Nau; Dawn Henson||Maria Vanegas||Available for Licensing|
|9,649,393||Magnetic Resonance Imaging Cell Labeling Methods and Compositions||David Schwartzman; Eric Ahrens||Janice Panza||Available for Licensing|
|9,649,300||Inhibition of WNT, TGF Beta and Hippo Signaling Pathways to Treat Cancer, Organ Fibrosis and Metabolic Disorders||Robert Lettan II; Abdelhadi Rebbaa||Andrew Remes||Available for Licensing|
|9,649,285||Treatment of Medium-Chain Acylcoa Dehydrogenase Deficiency||Al-Walid A. Mohsen; Gerard Vockley||Maria Vanegas||Available for Licensing|
|9,656,417||System and Method for Mandrel-less Electrospinning||William Wagner; John McGrath; Lorenzo Soletti; Mohammed Salim El Kurdi; J. Christopher Flaherty||Alex Ducruet||Available for Licensing|
|9,655,980||A Novel Theranostic Platform for Targeted Cancer Therapy and Drug Delivery Monitoring||Mingfeng Bai; Pin Shao||Maria Vanegas||Available for Licensing|
|9,655,869||Estrogen Antagonists as Treatments for Sclerosing Disorders||Carol Feghali-Bostwick; Pamela Anne Hershberger||Andrew Remes||Available for Licensing|
|9,655,950||Predictors of Patient Response to Interferon-A Therapy||Larisa Geskin; Oleg Akilov||Robert Racunas||Available for Licensing|
|9,662,035||Steady State Measurement and Analysis Approach to Profiling Auditory Evoked Potentials From Short Latency to Long Latency||John Durrant; Abreena Tlumak; Rafael Delgado||Maria Vanegas||Available for Licensing|
|9,662,329||Use of Survivin Antagonists in Polyomavirus-Related Disease||Patrick Moore; Yuan Chang||Maria Vanegas||Available for Licensing|